Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 year old males or females~* Patients with recurrent or metastatic renal cell carcinoma (RCC) or primary RCC that is not amendable to surgical intervention~* Histologically or cytologically confirmed renal cell carcinoma~* Measurable disease~* No more than one prior systemic treatment (chemotherapy or immunotherapy) for RCC.~* No active brain metastases~* Karnofsky performance status ≥ 70%, life expectancy ≥ 3 months~* No childbearing potential, or use of effective contraception during the study and for 4 weeks after the last dose of study drug~* Archival paraffin embedded tumor tissue, if available.~* Ability to give written informed consent~Exclusion Criteria:~* Pregnant or lactating women~* Primary CNS malignancies; active CNS metastases~* Hematologic malignancies (includes: leukemia, any form; lymphoma; and multiple myeloma)~* Any of the following hematologic abnormalities:~  * Hemoglobin ≤ 9.0 g/dL~ * ANC \< 1500 per mm3~ * Platelet count \< 100,000 per mm3~* Any of the following serum chemistry abnormalities:~  * Total bilirubin \> 1.5 × the ULN~ * AST or ALT ≥ 2.5 × the ULN~ * Serum albumin \< 3.0 g/dL~ * Creatinine \> 1.7 × ULN (or calculated CLCR \<50 mL/min/1.73 m2)~ * Proteinuria \> 2.5 g/24 hours or 4+ with urine dipstick~* Significant cardiovascular disease, including:~  * Active clinically symptomatic left ventricular failure~ * Active HTN (diastolic blood pressure \> 100 mmHg). Patients with a history of hypertension must have been on stable doses of anti-hypertensive drugs for ≥ 4 weeks~ * Uncontrolled hypertension: Blood pressure \>140/90 mmHg on more than 2 antihypertensive medications.~ * Myocardial infarction within 3 months prior to administration of first study dose~* Unhealed wounds (including active gastric ulcers)~* Serious/active infection; infection requiring parenteral antibiotics~* Inadequate recovery from prior antineoplastic therapy~* Inadequate recovery from any prior surgical procedure; major surgical procedure within 4 weeks prior to study entry~* Life-threatening illness or organ system dysfunction compromising safety evaluation~* Psychiatric disorder, altered mental status precluding informed consent or necessary testing~* Inability to comply with protocol requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Tivozanib (AV-951) administered as a solid dosage form daily for three weeks per month
- 2 (Type: PLACEBO_COMPARATOR): solid oral capsule containing excipients dosed daily for three weeks per month

Based on this trial design, predict the completion outcome and termination type (if applicable).